Navigation Links
Echo Therapeutics Announces Second Quarter 2012 Financial Results

PHILADELPHIA, Aug. 10, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the quarter ended June 30, 2012. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, is available through Echo's website at

(Logo: )

Recent Corporate Highlights

  • Echo announced that Platinum-Montaur Life Sciences, LLC will provide the Company a credit facility of up to $20 million.  This transaction will provide the Company with significant, yet flexible, financial resources to fund its development and growth plans.
  • Echo announced positive results from its clinical study conducted at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania.  This study is the second of two studies in critically ill patients that demonstrated that Symphony successfully and continuously monitored glucose levels in the intensive care unit.
  • Echo signed an amended license agreement with Ferndale Pharma Group, Inc. that expanded the territory in which Ferndale can develop, market and sell Prelude for needle-free skin preparation prior to the application of topical 4% lidocaine cream.
  • Echo was included in the Russell Microcap® Index when Russell Investments rebalanced its family of U.S. indexes.  A company's membership in the Russell Microcap Index, which remains in place for one year, means that it is automatically included in the appropriate growth and value style indexes.
  • At the 72nd Scientific Sessions of the American Diabetes Association, Echo presented an expanded analysis of data from its clinical trial of Symphony in subjects with either type 1 or type 2 diabetes.  Following the oral presentation, Echo hosted a panel discussion on hospital-based glucose control with Key Opinion Leaders in glycemic control. Video highlights are available:
  • David Walton, who has nearly two decades of strategic healthcare marketing experience, joined Echo as Vice President of Marketing and Commercial Development.  Dave leads global strategic marketing planning for Symphony and other new products in the Company's growth strategy.
  • "Montaur's financial commitment, together with the recent positive clinical results of Symphony and the appointment of Dave Walton to lead our global marketing effort, represent important achievements for Echo as we progress toward regulatory clearance and commercialization," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics.  "In the second half of the year, our focus is to establish plans for CE Mark and FDA pivotal trials for Symphony, advancing toward European and U.S. regulatory clearances and, ultimately, Symphony's commercial launch."

    Second Quarter 2012 Financial ResultsEcho's net loss for the second quarter of 2012 was $3.2 million, or ($0.08) per share, compared to $2.0 million, or ($0.06) per share, for the second quarter of 2011.  Operating loss for the second quarter of 2012 was $3.5 million compared to $1.8 million for the second quarter of 2011.  Research and development expenses were $2.2 million for the second quarter of 2012 compared to $1.0 million in the prior year.  The increase in research and development expenses are primarily related to increased manufacturing, development and clinical expenses, as well as personnel costs.  General and administration expenses were $1.3 million for the second quarter of 2012 versus $1.0 million in the prior year.  The increase in general and administrative expenses was primarily due to increased personnel and facility costs, as well as legal and other Nasdaq and public company expenses. Echo reported a cash balance of approximately $3.1 million as of June 30, 2012.Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:
    Christine H. Olimpio
    Director, Investor Relations and Corporate Communications
    (215) 717-4104
    colimpio@echotx.comConnect With Us:
    - Visit our website at
    - Follow us on Twitter at
    - Join us on Facebook at

     Echo Therapeutics, IncCondensed Consolidated Balance Sheets   June 30,2012December 31,2011ASSETSCurrent Assets:Cash and cash equivalents

    8,995,571Cash restricted pursuant to letters of credit

    407,463250,000Other current assets

    221,961317,940Total current assets

    3,740,7669,563,511Net property and equipment (including assets under capitalized leases)

    563,597317,731Intangible assets, net of accumulated amortization

    9,625,0009,625,000Restricted cash, deposits and other assets

    10,81620,565Total assets

    $  13,940,179$
    9,526,807LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

    365,298Deferred revenue

    123,721123,708Derivative warrant liability

    392,5361,035,337Accrued expenses and other liabilities

    745,384968,120Total current liabilities

    1,945,3132,492,463Deferred revenue, notes payable and capital lease obligation, net of current portion and discounts

    2,65665,755Total liabilities

    1,947,9692,558,218CommitmentsStockholders' Equity:Convertible preferred stock, Series C & D

    30,16030,160Common stock

    396,156385,442Additional paid-in capital

    99,276,01598,116,327Common stock subscribed for but not paid for or issued

    -6,667Accumulated deficit

    (87,710,121)(81,570,007)Total stockholders' equity

    11,992,21016,968,589Total liabilities and stockholders' equity

    $  13,940,179$


    Condensed Consolidated Statements of Operations Three Months EndedJune 30,Six Months EndedJune 30,2012201120122011Licensing revenue

    242,910Other revenue

    -37,065-145,152Total revenues

    30,927158,52061,854388,062Operating Expenses:Research and development

    2,200,307996,1493,591,9521,862,099Selling, general and administrative

    1,334,852978,1503,194,2561,900,265Total operating expenses

    3,535,1591,974,2996,786,2083,762,364Loss from operations

    (3,504,232)(1,815,779)(6,724,354)(3,374,302)Other Income (expense):Interest income (expense), net

    1,4226064,231(10,065)Loss on extinguishment of debt/payables

    ---(1,514)Gain (loss) on disposals of assets

    (21,272)(2,531)(21,272)834Derivative warrant liability gain (loss)

    369,738(122,011)601,281(3,151,908)Other income (expense), net

    349,888(123,936)584,240(3,162,653)Net loss


    Deemed dividend on beneficial conversion feature of
    Series D Convertible Preferred Stock

    ---(1,975,211)Accretion of dividends on Convertible Perpetual
    Redeemable Preferred Stock

    -(47,558)-(93,242)Net loss applicable to common shareholders

    (8,605,408)Net loss per common share, basic and diluted

    (0.26)Basic and diluted weighted average common shares


    SOURCE Echo Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
    2. Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences
    3. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
    4. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
    5. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
    6. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
    7. Silence Therapeutics - Admission of Shares and Board Update
    8. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
    9. OrPro Therapeutics Receives NIH Grant Award to Advance Development of Recombinant Thioredoxin for Treatment of Cystic Fibrosis
    10. Cell Therapeutics Announces Institutional Investor Purchased Additional $15 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
    11. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
    Post Your Comments:
    (Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
    (Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
    (Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
    Breaking Medicine Technology:
    (Date:11/27/2015)... Canada (PRWEB) , ... November 28, 2015 , ... There ... do we outperform our billings from last year? , This question has not been ... organizations are coming to the retirement age and the younger workforce don’t share the ...
    (Date:11/27/2015)... ... November 27, 2015 , ... The rapid ... America. As people age, more care is needed, especially with Alzheimer’s, dementia and ... professionals are being overworked. The forgotten part of this equation: 80 percent of ...
    (Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special ... 10% off of their purchase of lice treatment product. In addition, customers will receive ... a company spokesperson. “Finding lice is a sure way to ruin the holidays, so ...
    (Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
    (Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges faced ... and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities ... by parents and bring advice from parenting experts within their reach. As a ...
    Breaking Medicine News(10 mins):